Sci-Tech World Delaware
SEE OTHER BRANDS

Hottest science and technology news from Delaware

Sci-Tech World Delaware: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech World Delaware.

Press releases published on September 3, 2025

Legendary Scientist and Biotech Veteran Joins CancerVax as Strategic Advisor

Legendary Scientist and Biotech Veteran Joins CancerVax as Strategic Advisor

Lehi, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, September 3, 2025 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to treat cancer, today announced that Gordon Ringold, PhD has …

Renovamen Advisors® Launches to Help Early-Stage Biotechs Translate Breakthroughs into Scalable, Investable Business Models

Renovamen Advisors® Launches to Help Early-Stage Biotechs Translate Breakthroughs into Scalable, Investable Business Models

Renovamen Advisors® Launches to Help Early-Stage Biotechs Translate Breakthroughs into Scalable, Investable Business Models Guiding biotech teams from scientific breakthroughs to commercial inflection with investor-grade strategy and execution Chicago, IL …

nCino launches ProBanker by FullCircl, a new solution to help UK lenders identify opportunity and manage risk across their business portfolios

nCino launches ProBanker by FullCircl, a new solution to help UK lenders identify opportunity and manage risk across their business portfolios

LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ: NCNO), the leading provider of intelligent, best-in-class banking solutions, today announced the general availability of ProBanker by FullCircl. FullCircl, a technology acquired by nCino last …

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

Strong immune response after third yearly booster dose in children and adults Significant anamnestic antibody response across all six serotypes No safety concerns observed in any age group by independent Data Monitoring Committee (DMC), consistent with …

Valneva annonce de nouvelles données positives d’innocuité et d’immunogénicité de Phase 2 pour le candidat vaccin contre la maladie de Lyme

Valneva annonce de nouvelles données positives d’innocuité et d’immunogénicité de Phase 2 pour le candidat vaccin contre la maladie de Lyme

 Forte réponse immunitaire chez les enfants et les adultes après la troisième vaccination annuelle de rappel Forte réponse anamnestique observée pour les six sérotypes Aucun problème de sécurité observé dans toutes les tranches d’âge par le comité …

NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer

NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer

NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer Seasoned clinical development leader brings deep expertise in neuromuscular disease research, drug development, and commercialization in the US and …

ASK4SAM Cements Role As Best NYC Personal Injury Lawyers for Car Accidents in Queens & Bronx with 550th Google Review

ASK4SAM Cements Role As Best NYC Personal Injury Lawyers for Car Accidents in Queens & Bronx with 550th Google Review

Jamaica, NY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Silberstein …

Conversational AI Interview Tools Rolled Out to Streamline High-Volume Tech Hiring

Conversational AI Interview Tools Rolled Out to Streamline High-Volume Tech Hiring

Photo Courtesy of: Supportwave LONDON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Supportwave, a next-generation Tech staffing company, has launched a conversational interview platform aimed at overhauling technical hiring for enterprise clients. The platform …

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions